Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note released on Saturday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Other research analysts also recently issued reports about the company. HC Wainwright restated a “neutral” rating and issued a $6.60 price target on shares of Revance Therapeutics in a research note on Friday, November 8th. Mizuho lowered their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. Barclays cut their target price on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, December 23rd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Nine equities research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, Revance Therapeutics currently has an average rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Price Performance

Shares of RVNC stock opened at $3.06 on Friday. Revance Therapeutics has a one year low of $2.30 and a one year high of $9.74. The company’s fifty day moving average price is $4.12 and its 200-day moving average price is $4.49. The company has a market capitalization of $319.43 million, a price-to-earnings ratio of -1.59 and a beta of 0.81.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The business had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. Equities research analysts expect that Revance Therapeutics will post -1.57 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Revance Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Certuity LLC bought a new position in shares of Revance Therapeutics during the 2nd quarter valued at approximately $26,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of Revance Therapeutics in the second quarter valued at $33,000. Hsbc Holdings PLC bought a new stake in shares of Revance Therapeutics in the 2nd quarter worth about $38,000. FORA Capital LLC bought a new stake in shares of Revance Therapeutics in the 3rd quarter worth about $54,000. Finally, Creative Planning purchased a new position in shares of Revance Therapeutics during the 3rd quarter worth about $56,000. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.